Guarana (Paullinia cupana Mart.) prevents β-amyloid aggregation, generation of advanced glycation-end products (AGEs), and acrolein-induced cytotoxicity on human neuronal-like cells.
Advanced glycation end-products (AGEs) are considered potent molecules capable of promoting neuronal cell death and participating in the development of neurodegenerative disorders such as Alzheimer's disease (AD). Previous studies have shown that AGEs exacerbate β-amyloid (Aβ) aggregation and AGE-related cross-links are also detected in senile plaques. Acrolein (ACR) is an α, β-unsaturated aldehyde found in the environment and thermally processed foods, which can additionally be generated through endogenous metabolism. The role of ACR in AD is widely accepted in the literature. Guarana (Paullinia cupana Mart.) is popularly consumed by the population in Brazil, mainly for its stimulant activity. In the present study, we showed that guarana (10, 100, and 1000 µg/mL) is able to prevent protein glycation, β-amyloid aggregation, in vitro methylglyoxal, glyoxal, and ACR (20 μM)-induced toxicity on neuronal-like cells (SH-SY5Y). Since these are considered typical AD pathological hallmarks, we propose that guarana may deserve further research as a potential therapeutic agent in such a neurodegenerative disease.
Centro de Estudos em Estresse Oxidativo, Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil.
Leonardo da Silva
Lda S
Bittencourt
Fares
F
Zeidán-Chuliá
Francini Kiyono Jorge
FK
Yatsu
Carlos Eduardo
CE
Schnorr
Karla Suzana
KS
Moresco
Eduardo Antônio
EA
Kolling
Daniel Pens
DP
Gelain
Valquiria Linck
VL
Bassani
José Cláudio Fonseca
JC
Moreira
D000171:Acrolein / Q000009:adverse effects*; D016229:Amyloid beta-Peptides / Q000737:chemistry*; D000975:Antioxidants / Q000494:pharmacology; D001938:Brazil; D045744:Cell Line, Tumor; D017127:Glycation End Products, Advanced / Q000378:metabolism*; D006801:Humans; D009447:Neuroblastoma; D009474:Neurons / Q000187:drug effects*; D032126:Paullinia / Q000737:chemistry*; D010446:Peptide Fragments / Q000737:chemistry*; D010936:Plant Extracts / Q000494:pharmacology*; D066263:Protein Aggregation, Pathological / Q000517:prevention & control*; D017382:Reactive Oxygen Species / Q000378:metabolism
D016229:Amyloid beta-Peptides; D000975:Antioxidants; D017127:Glycation End Products, Advanced; D010446:Peptide Fragments; D010936:Plant Extracts; D017382:Reactive Oxygen Species; C075222:amyloid beta-protein (1-42); D000171:Acrolein
Alzheimer's disease; caffeine; natural products; neurodegenerative diseases; neuroprotection; polyphenols